华润双鹤5亿元产业基金完成备案，全面助力合成生物第二增长曲线

Group 1 - The establishment of the "China Resources Double Crane Biopharmaceutical Industry Fund" with a scale of 500 million yuan focuses on key technologies and high-tech achievement transformation projects in synthetic biology and related fields [1] - This fund is the first industry fund of China Resources Group dedicated to synthetic biology, aligning with the group's strategic initiative in emerging industries [1][3] - The company aims to create a second growth curve through synthetic biology, promoting significant development during the 14th Five-Year Plan period [1][3] Group 2 - China Resources Double Crane has over 80 years of experience in the pharmaceutical industry and operates 24 subsidiaries with approximately 13,000 employees, achieving annual sales exceeding 10 billion yuan [3] - The company has set two strategic goals for the 14th Five-Year Plan: to establish its core chemical drug business as "China's leading prescription drug brand" and to leverage synthetic biology technology for new growth [3] - The company’s subsidiary, Shenzhou Biotechnology, is a key platform for the industrialization of synthetic biology, with its core product, coenzyme Q10, holding the second-largest global market share [3] Group 3 - Synthetic biology is leading a global biotechnological revolution with vast market potential across various sectors, including food, healthcare, biomaterials, green agriculture, and personal care [4] - The fund will complement the company's external mergers and acquisitions, facilitating early-stage project innovation and integration with invested companies in technology, production, and market aspects [4] - The collaboration between China Resources Double Crane and the Hohhot municipal government will enhance the competitiveness of the synthetic biology industry, leveraging local resource advantages for large-scale fermentation production [4]